Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
– Continued active enrollment of Olvi-Vec in our pivotal Phase 3 OnPrime/GOG-3076 trial in platinum resistant/refractory ovarian cancer with topline results anticipated in 2H 2025 –
– Initiation of Phase 2 trial in non-small cell lung cancer (recurrent/platinum-ICI failure) with systemic administration of Olvi-Vec expected in 1H 2024 –
– Ongoing Phase 1b/2 trial with systemic administration of Olvi-Vec in small cell lung cancer expected interim readout in 2H 2024 –
– $23.2 million in cash, cash equivalents and short-term investments –
“Last year was highlighted by the ongoing advancement of our clinical pipeline focused on platinum re-sensitization, including our pivotal Phase 3 trial in platinum resistant/refractory ovarian cancer and development of our two systemic administration trials in lung cancer,” said
Pipeline Updates
- Actively enrolling patients in ongoing Phase 3 OnPrime/GOG-3076 registrational trial in platinum resistant/refractory ovarian cancer (PRROC) in
the United States . Currently, 21 sites have been activated to enroll patients with additional sites identified and in various stages of activation (NCT05281471). On track for topline results in 2H 2025. FDA Fast Track designation previously granted by the FDA. - Patient enrollment has been increasing in the ongoing Phase 1b part of the Phase 1b/2 trial in patients with recurrent small cell lung cancer. Building on data from early clinical trials, Olvi-Vec is being systemically administered, a physician-preferred route of delivery.
Genelux and our partner Newsoara co-sponsor the trial, which is being conducted by Newsoara in greaterChina . The lead investigator is renowned clinician ProfessorShun Lu , M.D., Ph.D. of the prestigious Shanghai Chest Hospital, School of Medicine,Shanghai Jiao Tong University ,Shanghai China . Interim readout anticipated in 2H 2024. - Initiation of the Phase 2 non-small cell lung cancer trial is anticipated to begin in the 1H 2024. Patients will receive Olvi-Vec through systemic administration.
Business Updates
- The Company filed a shelf registration statement on Form S-3 with the
Securities and Exchange Commission (SEC). Under the shelf registration statement,Genelux may offer and sell, from time to time, up to$300.0 million in common stock, preferred stock, debt securities and/or warrants in one or more offerings. Concurrent with the shelf registration, the Company entered into a sales agreement under which the Company may offer to sell shares of our common stock up to$100.0 million throughGuggenheim Securities , acting as our agent. - In 2023, the Company grew the core management team to further bolster the development of Olvi-Vec.
- As
Genelux's clinical trial program progresses and diversifies, the company intends to expand its preliminary commercial strategy initiatives and support corporate development efforts.
Fourth Quarter 2023 and Yearly Financial Results
Cash, cash equivalents and short-term investments were
Research and development (R&D) expenses were approximately
General and administrative (G&A) expenses were approximately
Net loss was approximately
About
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “believes,” “anticipates,” “expect,” “may,” “plan” or “will”. Forward-looking statements in this release include, but are not limited to, statements related to Genelux’s future plans and prospects, Genelux’s anticipated cash runway and the sufficiency of its resources to support its planned operations, the planned timing of the Genelux’s data results and continued development of Olvi-Vec, the planned initiation of the Phase 2 non-small cell lung cancer trial and the timing thereof; and the potential capabilities and advantages of Olvi-Vec. Such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements. These and other risks are identified under the caption “Risk Factors” in Genelux’s filings with the
Investor and Media Contacts
genelux@allelecomms.com
Source:
| Balance Sheets | ||||||
| (In thousands, except for share amounts and par value data) | ||||||
| 2023 | 2022 | |||||
| ASSETS | ||||||
| Current Assets | ||||||
| Cash and cash equivalents | $ | 9,418 | $ | 397 | ||
| Short-term investments | 13,773 | - | ||||
| Prepaid expenses and other current assets | 1,012 | 1,495 | ||||
| Total Current Assets | 24,203 | 1,892 | ||||
| Property and equipment, net | 1,170 | 644 | ||||
| Right of use assets | 2,428 | 1,335 | ||||
| Deferred offering costs | - | 1,568 | ||||
| Other assets | 92 | 92 | ||||
| Total Other Assets | 3,690 | 3,639 | ||||
| TOTAL ASSETS | $ | 27,893 | $ | 5,531 | ||
| LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT) | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued expenses | $ | 3,784 | $ | 6,775 | ||
| Accrued payroll and payroll taxes | 2,117 | 2,852 | ||||
| Accrued interest payable | - | 1,178 | ||||
| Accrued interest payable - director and shareholders | - | 3,817 | ||||
| Deferred revenue | - | 170 | ||||
| Warrant liabilities | - | 169 | ||||
| Lease liability, current portion | 653 | 266 | ||||
| Notes payable - shareholders, net of debt discount of |
- | 992 | ||||
| Convertible notes payable - shareholders, current portion | - | 15,407 | ||||
| Total Current Liabilities | 6,554 | 31,626 | ||||
| Long-term Liabilities | ||||||
| Lease liability, long-term portion | 1,866 | 1,164 | ||||
| Convertible notes payable, net of debt discount of |
- | 8,524 | ||||
| Total Long-term Liabilities | 1,866 | 9,688 | ||||
| Total Liabilities | 8,420 | 41,314 | ||||
| Shareholders' Equity (Deficit) | ||||||
| Preferred stock, Series A through K, par value |
- | 22 | ||||
| Common stock, par value |
27 | 9 | ||||
| (433 | ) | (433 | ) | |||
| Additional paid-in capital | 241,389 | 154,401 | ||||
| Accumulated other comprehensive income | 14 | 2 | ||||
| Accumulated deficit | (221,524 | ) | (189,784 | ) | ||
| Total Shareholders' Equity (Deficit) | 19,473 | (35,783 | ) | |||
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT) | $ | 27,893 | $ | 5,531 | ||
| The accompanying notes are an integral part of these financial statements. | ||||||
| Statements of Operations | ||||||
| (in thousands, except for share amounts and per share data) | ||||||
| Years Ended | ||||||
| 2023 | 2022 | |||||
| Revenues | $ | 170 | $ | 11,068 | ||
| Operating expenses: | ||||||
| Research and development | 12,767 | 9,078 | ||||
| General and administrative | 11,568 | 5,003 | ||||
| Total operating expenses | 24,335 | 14,081 | ||||
| Loss from operations | (24,165 | ) | (3,013 | ) | ||
| Other income (expenses): | ||||||
| Interest income | 244 | - | ||||
| Interest expense | (173 | ) | (1,150 | ) | ||
| Debt discount amortization | (649 | ) | (258 | ) | ||
| Financing costs | (3,152 | ) | - | |||
| Debt extinguishment costs | (402 | ) | - | |||
| Gain on forgiveness of PPP loan payable | - | 314 | ||||
| Total other income (expenses), net | (4,132 | ) | (1,094 | ) | ||
| Loss before provision for foreign income taxes | (28,297 | ) | (4,107 | ) | ||
| Provision for foreign income taxes | - | (1,100 | ) | |||
| NET LOSS | $ | (28,297 | ) | $ | (5,207 | ) |
| LOSS PER COMMON SHARE - BASIC AND DILUTED | $ | (1.16 | ) | $ | (0.57 | ) |
| WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING - BASIC AND DILUTED | 24,429,278 | 9,116,489 | ||||
| The accompanying notes are an integral part of these financial statements. | ||||||
| Statements of Comprehensive Loss | ||||||
| (in thousands) | ||||||
| Years Ended | ||||||
| 2023 | 2022 | |||||
| Net loss | $ | (28,297 | ) | $ | (5,207 | ) |
| Other comprehensive loss: | ||||||
| Net unrealized gain on short-term investments | 12 | - | ||||
| Comprehensive loss | $ | (28,285 | ) | $ | (5,207 | ) |
| The accompanying notes are an integral part of these financial statements. | ||||||
Source: Genelux Corporation